Investment management company Baron Funds has announced the first quarter 2024 investor letter for Baron Asset Fund. A copy of the letter can be downloaded here. The US market continued its strong rise in the first quarter. Strong economic data and relatively strong corporate profits fueled the rally, along with hopes for a soft market landing. The fund rose 6.00% in the quarter, compared to the Russell MidCap Growth Index's 9.50% rise and the S&P 500's 10.56% rise. Headwinds from stock selection and the fund's long-standing style bias caused the fund to underperform in the first quarter. Plus, check out the fund's top 5 holdings to find out the best stocks for 2024.
Baron Asset Fund featured stocks such as Biotechne Corporation (NASDAQ:TECH) in its Q1 2024 Investor Letter. Bio-Techne Corporation (NASDAQ:TECH), headquartered in Minneapolis, Minnesota, develops and manufactures reagent solutions, instruments and services for the research and clinical diagnostic markets. On May 13, 2024, Biotechne Corporation (NASDAQ:TECH) stock closed at $81.97 per share. Bio-Techne Corporation (NASDAQ:TECH)'s 1-month return is his 28.06%, and the company's stock has increased his 0.04% in value over the past 52 weeks. Bio-Techne Corporation (NASDAQ:TECH) has a market capitalization of $12.917 billion.
Baron Asset Fund said the following about Bio-Techne Corporation (NASDAQ:TECH) in its Q1 2024 investor letter:
“Bio-Techne Corporation (NASDAQ:TECH) is a leading developer and manufacturer of reagents, instruments, and services for the life sciences research, diagnostics, and bioprocessing markets, after the company reported weak fourth-quarter results. ” Management noted that business in China was stabilizing and the financing environment was beginning to recover, but did not expect any significant improvement until later. We believe these headwinds are cyclical and are encouraged by signs of stabilization in the company's business, leaving Biotechne well-positioned for long-term growth. I continue to believe that. ”
Close-up of a laboratory technician handling medical equipment used in infertility treatment.
Bio-Techne Corporation (NASDAQ:TECH) isn't on the list of 30 most popular stocks among hedge funds. Our database shows that Biotechne Corporation (NASDAQ:TECH) was held by 23 hedge fund portfolios at the end of the fourth quarter, compared to 25 in the prior quarter. Additionally, for investor letters from hedge funds and other leading investors, please visit our Hedge Fund Investor Letters Q1 2024 page.
story continues
In another article, we discussed Bio-Techne Corporation (NASDAQ:TECH) and shared a list of the world's largest biotech companies. Polen Capital added his Bio-Techne Corporation (NASDAQ: TECH) to its portfolio last quarter and shared his optimism about its long-term growth prospects.
Recommended articles:
Disclosure: None. This article was originally published on Insider Monkey.
